AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02196350 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention A: Diet
Description: subjects visit the dietitian at week 0, 1, 2, 6, 10 and 13 for dietary advice
Study NCT05016830 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Bilateral transcranial direct current stimulation
Description: A direct current is applied with two electrodes (cathode and anode) in specific parts of the skull. In this case the anode was over the occipital area to target the amblyopic cortex, while the cathode was over the contralateral side, targeting the fellow cortex.
Study NCT02003469 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ambulatory Blood Pressure Monitoring
Description: All enrolled patients have an ambulatory blood pressure monitor placed, pre-transplant/donation, again at 3 months and finally at 12 months post-transplant/donation to measure blood pressure and blood pressure patterns
Study NCT03312712 — intervention group
Intervention type: OTHER
Intervention: LPS Challenge
Description: In Part B, eight healthy volunteers will undergo an LPS challenge whereby each participant is injected with the challenge agent, Lipopolysaccharide (LPS), to invoke temporary mild lung inflammation. Each participant will have a PET/CT scan before and after the administration of LPS and the images will be assessed to determine whether these methods are able to detect true lung inflammation.
Study NCT03312712 — intervention group
Intervention type: OTHER
Intervention: Saline Challenge
Description: In Part B, four healthy volunteers will undergo a saline challenge as outlined above for the LPS challenge. Pre- and post-challenge scans will provide control data for the study.
Study NCT03312712 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood and urine sampling
Description: For women whose post-menopausal status and/or pregnancy status is uncertain at screening, a blood sample will be collected to test for pregnancy and menopausal status (hormone profiling) before enrolling them on to the study. If pregnancy status is still uncertain at study visits, participants will have a urine pregnancy test before undergoing any PET/CT scans to ensure it is safe for them to continue in the study.
Study NCT02196350 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention B: Exercise
Description: subjects visit the physiotherapist three times weekly; subjects visit the dietitian at week 0, 1, 2, 6, 10 and 13 for dietary advice.
Study NCT02196350 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention C: Diet and Exercise
Description: subjects visit the physiotherapist three times weekly; subjects visit the dietitian at week 0, 1, 2, 6, 10 and 13 for dietary advice.
Study NCT04108650 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fit & Strong! group
Description: Consistent with the original format of F\&S!, the classes met three times per week for 90 minutes each for 8 weeks (24 sessions in total). Each class session consisted of 60 minutes of exercise and 30 minutes of health education. The exercise protocol included 10 minutes of warm-up and cool-down exercises, 20 minutes of low-intensity aerobic exercises, and 20 minutes of lower extremity strengthening exercises. The health education program focused on symptom management and behavioral strategies to increase physical activity and commitment to lifestyle change.
Study NCT04278404 — intervention group
Intervention type: DRUG
Intervention: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
Description: The prescribing of drugs to children is not part of this protocol. Participants will receive DOIs as prescribed by their treating provider.
Study NCT01784029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Doses are as mentioned above. Will repeat 3 month cycles of treatment if still deficient at 3 month follow up.
Study NCT04551300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VS-505
Description: 4 dosages of experimental drug
Study NCT04176588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrasimod
Description: Drug:Etrasimod Tablet other name:APD334
Study NCT04176588 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug:placebo Tablet
Study NCT04551300 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevelamer Carbonate
Description: Active Comparator
Study NCT00822302 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reconstituted High Density Lipoprotein
Description: RecHDL (Lot Nos 05422-00006)is provided as a lyophilised powder and reconstituted with sterile water at 25 mg/ml. The infusion is made at 40 mg/kg over a period of 4 hours.
Study NCT00822302 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline (0.9%) is provided as a sterile infusion bag and infused over a period of 4 hours, 24 hours prior to carotid endarterectomy
Study NCT02840630 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tinned mackerel fish
Description: Diabetic fish intervention group will be given two tinned mackerels per week from week 0 until week 16.
Study NCT02665910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0302
Description: Oral tablets (1 mg, 5 mg, 10 mg)
Study NCT02665910 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SHR0302 placebo comparator
Description: Oral tablets (1 mg, 5 mg, 10 mg) (matching corresponding study medication)
Study NCT04129307 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor imagery
Description: This group will perform motor imagery training in combination with physical practice on motor learning of different motor tasks.
Study NCT04129307 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Double time motor imagery
Description: This group will perform motor imagery training by doubling the intervention time to the motor imagery group in combination with physical practice on motor learning of various motor tasks.
Study NCT04129307 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Action observation
Description: This group will perform action observation training in combination with physical practice on motor learning of various motor tasks.
Study NCT01147302 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01147302 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C1 Esterase Inhibitor (Human)
Study NCT01843530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berinert
Study NCT01843530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clemastin
Study NCT01843530 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clemastin
Study NCT01843530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cortisone acetate
Study NCT01843530 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cortisone acetate
Study NCT01843530 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl
Study NCT01853709 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Study NCT01853709 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Study NCT03926936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: intramuscular injection (2x 250mg), once every 2 weeks for the first month, and then monthly until completion of the study
Study NCT05600647 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electromagnetic Field therapy with an exercise program
Description: 1. The magnetic field is generated through a mattress that is connected to the device. The maximum program, program 4, for 20 minutes with an intensity of 35 microtesla (level 10) and 50-60 Hz. the patient was lying on the mattress in a supine position.~2. the exercise program included postural correction strengthening exercises, stretching, proprioception and balance training
Study NCT05600647 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise program
Description: the exercise program included postural correction, strengthening exercises, stretching, proprioception and balance training
Study NCT00145249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amphotericin B
Description: Amphotericin B 0.7 mg/kg IV for the first 14 days of treatment. This period may be extended up to an additional 7 days.
Study NCT00145249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amphotericin B
Description: Amphotericin B 0.7 mg/kg IV for the first 14 days of treatment. This period may be extended up to an additional 7 days.
Study NCT00145249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: Fluconazole 400 or 800 mg daily. Among subjects whose baseline weight is less than 40 kg, randomized fluconazole doses will be 200 mg/kg daily or 400 mg/kg daily.
Study NCT00145249 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluconazole
Description: Fluconazole 400 or 800 mg daily. Among subjects whose baseline weight is less than 40 kg, randomized fluconazole doses will be 200 mg/kg daily or 400 mg/kg daily.
Study NCT04653142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 765063
Description: BI 765063
Study NCT04653142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 754091
Description: BI 754091
Study NCT03529383 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Connected device
Description: Women will receive a connected wristband (https://www.carefitness.com/) and a subscription to a smartphone application and website (http://disco.biomouv.com/). They will have to participate in a 6-month personalized non-supervised exercise program consisting of 3 weekly sessions of 20 min to 1-hr of moderate-to-vigorous physical activity (≥3 METs): 2 sessions of brisk walking and 1 session of muscle strengthening. Women should wear the wristband daily to track their number of steps (automatic Bluetooth synchronization to the application). Duration and intensity of sessions and target number of daily steps will progressively increase (+15% up to 10,000 steps) to place the patients in a progression dynamic. Women will receive phone-based follow-up at 1 week, 2 months, and 4 months.
Study NCT03529383 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic education
Description: Women will be invited to participate in the 6-month therapeutic patient education program Mieux manger, mieux bouger (Eat better, move better) elaborated at the Léon Bérard cancer center. The program consists in four sessions:~* a 1-hour individual session of educational diagnosis to assess their needs and establish a contract of objectives,~* two educational sessions of 1h30 each using tools, in group of 10 patients maximum to improve their daily practice of physical activity,~* a 1-hour individual session of educational assessment to evaluate whether their objectives were reached.
Study NCT04305886 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discussion Guide
Description: Written list of prompts to facilitate discussion
Study NCT03667911 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual reality videos
Description: Watch virtual reality videos after routine patient education(both oral and written instructions). Videos give instructions on correct steps of bowel preparation, points for attention, as well as actual images of bowel during colonoscopy in the case of both excellent and unsatisfactory bowel preparation.
Study NCT01305252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: treprostinil inhalations
Description: Treprostinil inhalation QID starting at 3 breaths per inhalation \& gradually increasing to 9 breaths. Each breath provides approximately 6mcg of treprostinil.
Study NCT01305252 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tadalafil
Description: tadalafil 20mg QD PO increasing to 40mg QD as tolerated
Study NCT02259543 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Root conditioning with citric acid+tetracycline solution
Description: Application of a citric acid + tetracycline gel solution (1:1) for decontamination of root surfaces during the treatment of recession defects by subepithelial connective tissue graft
Study NCT01116635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin, superabsorbent polymer microspheres, embolotherapy
Description: varying doses of doxorubicin loaded onto SAP during embolization procedure. Pharmacokinetic analysis of elution profile through serum concentrations over 1 month period embolization of surgically resectable HCC with superabsorbent polymer microspheres loaded with doxorubicin from a single treatment. Phase I will follow a modified Fibonacci sequence (with pharmacokinetic analysis of serum doxorubicin) to determine mean tolerated dose (MTD), severe adverse reaction (SAE) and dose limiting toxicities (DLT) when microspheres are loaded with 25mg, 50mg, or 75mg of doxorubicin. Phase II will continue enrollment with the two highest tolerated doses. At least one month after treatment, all patients will undergo imaging and surgical resection of reference tumor, with assessment of degree of necrosis, microsphere distribution, and correlation with concentration of doxorubicin loaded onto microsphere.
Study NCT03625622 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AR1001
Description: AR1001 Active Oral Tablet
Study NCT03625622 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Oral Tablet
Study NCT03032913 — intervention group
Intervention type: PROCEDURE
Intervention: Blood samples
Description: Blood samples for both group
Study NCT03032913 — intervention group
Intervention type: PROCEDURE
Intervention: Portal vein blood sample
Description: Portal vein blood sample during surgery procedure for the Pancreatic Ductal Adenocarcinoma group
Study NCT01714960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRZ-99030 eye drops 5mg/mL
Study NCT01714960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRZ-99030 eye drops 20mg/mL
Study NCT01714960 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to MRZ-99030 eye drops
Study NCT03409913 — intervention group
Intervention type: RADIATION
Intervention: FDG PET/CT
Description: Conventional FDG PET/CT including head in order to asses cranial arteries.
Study NCT03311893 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: natural orifice surgery
Description: evaluation of the awareness of the use of transvaginal, transoral and transcranial approach in surgical excision and the difference between the health staff and the pathology
Study NCT03509714 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Jubilance (100 mg Oxaloacetate/150 mg Ascorbic Acid)
Description: 2 Pills to be taken orally per day during their entire menstrual cycle
Study NCT03509714 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: rice flour (Placebo)
Description: 250 mg rice flour (Placebo)
Study NCT04126616 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: chest Magnetic Resonance Imaging (MRI) using Gadolinium-based contrast agent
Description: chest MRI will be performed at rest and after moderate exercise
Study NCT04126616 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: chest Magnetic Resonance Imaging (MRI) using Gadolinium-based contrast agent
Description: chest MRI will be performed at rest and after moderate exercise
Study NCT01583517 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biliary sphincterotomy
Description: Cutting of the biliary sphincter muscle.
Study NCT01583517 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreatobiliary sphincterotomy
Description: Cutting of both the biliary and pancreatic sphincter muscles.
Study NCT01583517 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: No sphincterotomy is performed in patients randomized to sham with normal SOM.
Study NCT03507413 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Glucophage 500mg (IR) tablets M90
Description: oral metformin Glucophage treatment 500 mg daily (2-0-2) for 1 year
Study NCT03507413 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo Oral Tablet M90 treatment twice daily (2-0-2) for 1 year
Study NCT03176368 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coconut Oil
Description: Coconut Oil
Study NCT01393457 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levodopa/carbidopa
Description: 800/200 mg/d
Study NCT01393457 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropinirole 2 mg/d
Description: 2 mg/d
Study NCT01393457 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sugar pill
Study NCT01393457 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropinirole 4 mg/d
Description: 4 mg/d
Study NCT04704349 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Scintigraphy
Description: The scintigraphy of the patients will be carried out on 2 distinct devices and the images obtained will be compared.
Study NCT03840252 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 3D gait analysis
Description: Computed analysis of posture and gait pattern and motor performance by kinematic and kinetics parameters analysis such as the step length, gait velocity, stride time variability, 3D joint kinematics, ground reaction forces, joint kinetics
Study NCT03840252 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: rsfMRI
Description: MR scans acquired by 1.5 Tesla (Siemens Medical Systems, Erlangen, Germany).
Study NCT03840252 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Montreal Cognitive assesment (MoCA)
Description: Standard clinical questionnaire
Study NCT00426010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: caffeine/placebo
Description: caffeine or placebo, either overt or covert
Study NCT01264549 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Procalcitonin assay - B.R.A.H.M.S PCT ultrasensitive Kryptor
Description: The physician will be given access to a PCT value for Day 1 - 7. Depending on the PCT concentrations, the protocol recommends or discourages from the use of antibiotics
Study NCT03986450 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced recovery after surge(ERAS) protocol
Description: The components of ERAS multidisciplinary pathway concerning preoperative, operative, and postoperative period are as follows:~1. Preoperative care:~   Counseling before hospital admission Fluid, and carbohydrate loading Avoiding prolongation of the fasting period Avoiding bowel preparation or its application only in selective cases Application of antibiotic prophylaxis Application of thromboprophylaxis~2. Perioperative care:~Use of short-acting anesthetic agents Application of midthoracic, epidural anesthesia/analgesia Refraining from using drains Refraining from salt, and water overload Maintenance of normothermia~Postoperative care:~Application of midthoracic, epidural anesthesia/analgesia Prevention of nausea, and vomiting Refraining from salt, and water overload Earlier removal of catheters Initiation of oral intake at an early period Use of nonopioid oral analgesics/NSAIDs Early mobilization
Study NCT02794259 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Study NCT02794259 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham-tDCS
Study NCT02243293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493
Description: Tablet
Study NCT01853709 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fiber free diet
Study NCT01853709 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fiber free diet
Study NCT01853709 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Adjuvants
Study NCT01853709 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene glycol (PEG)
Study NCT01853709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol (PEG)
Study NCT01853709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisacodyl
Study NCT01706484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNO 1016
Description: comparison of different dosages of drug and placebo
Study NCT01706484 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BNO 1016
Description: comparison of different dosages of drug and placebo
Study NCT02483364 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HC-SVT-1001(initial protocol); HC-SVT-1002 (protocol amendment)
Description: A single application in the context of a single surgical intervention.
Study NCT03186638 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Given PO
Study NCT03186638 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO
Study NCT03186638 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03186638 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02550314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fiblast,gelatin sponge,fibrin glue
Study NCT03444818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-E6007
Description: Oral administration